No, Evenity Does Not Lower Morning Cortisol
Evenity (romosozumab) does not affect morning cortisol levels. This medication is a monoclonal antibody that targets sclerostin to promote bone formation and has no mechanism of action involving the hypothalamic-pituitary-adrenal (HPA) axis or adrenal steroid production.
Why This Question Arises
The provided evidence focuses entirely on:
- Immune checkpoint inhibitor-related endocrine adverse events (adrenal insufficiency, hypophysitis) 1, 2
- Glucocorticoid-induced adrenal insufficiency 3
- Romosozumab efficacy and safety for osteoporosis 4, 5, 6, 7, 8, 9, 10, 11
None of these sources indicate any relationship between romosozumab and cortisol levels.
Romosozumab's Actual Effects
According to the FDA label, romosozumab's known adverse effects include 5:
- Cardiovascular events (boxed warning for MI/stroke risk)
- Hypersensitivity reactions
- Hypocalcemia (not hypocortisolism)
- Injection site reactions
- Osteonecrosis of the jaw
- Atypical femoral fractures
No endocrine effects on the adrenal axis are documented in clinical trials involving 7,990 patients 5, 6.
Clinical Implications
If a patient on Evenity presents with symptoms suggesting adrenal insufficiency (fatigue, hypotension, hyponatremia):
- Do not attribute this to romosozumab
- Evaluate for other causes: concurrent glucocorticoid use, autoimmune adrenalitis, pituitary pathology, or malignancy
- Check morning cortisol and ACTH as clinically indicated 3
Bottom Line
Evenity has no pharmacologic mechanism to suppress cortisol production and no clinical trial evidence of adrenal suppression. Morning cortisol levels should remain unaffected by this osteoporosis therapy.